Lumera, Plexera, Miraculins, Kinaxo Biotechnologies, Power3, Panacea, Crucell | GenomeWeb
Lumera Spins out Plexera to Focus on Proteomics Work
Lumera this week said it has formed a wholly owned subsidiary, Plexera Biosciences, which will concentrate on proteomics research. Lumera has transferred its biosciences operations to the new company.
Plexera will provide the life sciences market with tools, content, and methods to “simplify and accelerate proteomic discovery for therapeutic antibodies as well as predictive biomarkers,” Lumera said in a statement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.